Open-Label Extension Study of GSK1605786A (SHIELD-3)
An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease
Sponsor: GlaxoSmithKline
Terminated
This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based on the results of Study CCX114151.
A PHASE3 clinical study on Crohn's Disease, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 14 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Oct 2017 — May 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Abbotsford, Canada , Adelaide, Australia , Afula, Israel , Aichi, Japan , Anaheim, United States , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Atlanta, United States and 196 more locations